Wells Fargo downgraded Zymeworks (ZYME) to Equal Weight from Overweight with an unchanged price target of $12. The firm believes the shares are “fully valued” following the company’s Q3 report. Wells cites valuation for the downgrade.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Zymeworks downgraded to Equal Weight from Overweight at Wells Fargo
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App